Manish A Shah, MD, talks about a recent phase II study of FOLFOX with or without onartuzumab, a MET inhibitor, for the treatment of metastatic gastroesophageal adenocarcinoma.
Manish A Shah, MD, director of gastrointestinal oncology at Weill Cornell Medical College/New York Presbyterian Hospital, talks about a recent phase II study of FOLFOX with or without onartuzumab, a MET inhibitor, for the treatment of metastatic gastroesophageal adenocarcinoma (GEC).
Clinical Pearls:
Brahmer Considers First-Line Immunotherapy Options in Metastatic NSCLC
February 17th 2025During a Case-Based Roundtable® event, Julie R. Brahmer, MD, MSC, reviewed the CheckMate 9LA, KEYNOTE-407, and POSEIDON trials of immunotherapy in patients with metastatic non–small cell lung cancer.
Read More